Sellas Life Sciences Group Inc expected to post a loss of 35 cents a share - Earnings Preview

Sellas Life Sciences

07/08/2023 13:23

* Sellas Life Sciences Group Inc  SLS.OQ   SLS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 9 (estimated). 
    * The New York City-based  company is expected to report
revenue
of $3.25 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Sellas Life
Sciences
Group Inc is for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sellas Life
Sciences Group Inc is $6​, above​ its last closing price
of $1.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.29       -0.29      -0.47     Missed  -61.1
 Dec. 31 2023  -0.34       -0.32      -0.43     Missed  -34.4
 Sep. 30 2022  -0.39       -0.39      -0.34     Beat    12.1​
 Jun. 30 2022  -0.35       -0.35      -0.41     Missed  -17.1
 ​​Mar.        -0.38       -0.38      -1.05     Missed  -176.3
 31 2022                                                
 Dec. 31 2021  -0.45       -0.41      -0.42     Missed  -2.4​
 Sep. 30 2021  -0.41       -0.38      -0.45     Missed  -19.5
 Jun. 30 2021  -0.40       -0.39      -0.30     Beat    23.1
 This summary was machine generated August 7 at 12:23 GMT.  All
figures in US dollars  unless otherwise stated